Compare AVNS & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNS | CAPR |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2014 | 2011 |
| Metric | AVNS | CAPR |
|---|---|---|
| Price | $24.80 | $31.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $44.63 |
| AVG Volume (30 Days) | ★ 2.0M | 1.0M |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.59 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $701,200,000.00 | N/A |
| Revenue This Year | $3.28 | N/A |
| Revenue Next Year | $4.23 | $3.31 |
| P/E Ratio | $225.41 | ★ N/A |
| Revenue Growth | ★ 1.95 | N/A |
| 52 Week Low | $9.30 | $4.30 |
| 52 Week High | $24.81 | $40.37 |
| Indicator | AVNS | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 90.70 | 46.63 |
| Support Level | $12.75 | $26.06 |
| Resistance Level | N/A | $36.66 |
| Average True Range (ATR) | 0.07 | 2.11 |
| MACD | -0.33 | -0.46 |
| Stochastic Oscillator | 64.52 | 41.25 |
Avanos Medical Inc is a medical technology company engaged in the development and commercialization of products for pain management and patient care. The company has two reportable segments: Specialty Nutrition Systems and Pain Management and Recovery. The Specialty Nutrition Systems segment provides enteral feeding and neonatal products. The Pain Management and Recovery segment offers surgical pain and recovery products, including pain pumps and radiofrequency ablation solutions for the treatment of chronic pain.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.